Grant: Discovery Grants Program - Individual
Université Laval
$35,000.00
Deciphering the role of RANK/RANKL/OPG in skeletal muscle
EF 2017-18
Résumé
The discovery of RANK/RANKL/OPG the receptor-activator of nuclear factor B (RANK), the receptor-activator of nuclear factor B ligand (RANKL), and the osteoprotegerin (OPG) pathway has been among the most important advances in bone biology and disease. RANK/RANKL/OPG form a key cytokine system for regulating osteoclast differentiation and function. RANKL is expressed by osteoblasts while RANK, its receptor, is expressed on pre-osteoclastic cells. The RANK/RANKL interaction induces the formation of multinucleated mature osteoclasts, ultimately causing bone resorption. However, the third protagonist, OPG, is also produced by osteoblasts and exerts an inhibitory effect on pre-osteoclastic differentiation. OPG, by binding to RANKL, inhibits the RANKL/RANK interaction and the subsequent osteoclastogenesis. The fact that OPG-null mice are osteoporotic is testimony to the physiological importance of OPG. OPG also serves as a decoy receptor for the tumour necrosis factor-related apoptosis-inducing ligand and increases cell survival by blocking the pro-apoptotic effects of the RANK/RANKL interaction. OPG is thus a very efficient anti-resorptive and anti-apoptotic agent. However, our recent publication in Am. J. Pathol. (2015) convincingly showed that OPG-Fc completely restores the function of fast-twitch extensor digitorum longus muscles and significantly improves the function of slow-twitch soleus and diaphragm muscles in mdx mice, indicating that OPG is not only a protector of bone but also skeletal muscles. In this proposal, we will use genetic and pharmacological approaches to determine how RANK/RANKL/OPG triad, known for its role in bone regulation, regulates skeletal muscle phenotype, muscle function and SERCA-2a content and SERCA activity. We have also accumulated substantial evidence to support the observation that RANKL binds to muscle RANK but RANKL/OPG would also have its own muscle receptor acting directly on skeletal muscle. We thus intend to pursue three specific aims over the next 5 years. (1) To understand the interplay between OPG, RANKL, mechanical loading and extracellular Ca2+ in muscle cells in culture. (2) To determine how extracellular Ca2+ influences muscle performance in dystrophic muscle RANK deficient mice. (3) To demonstrate that RANKL influences SERCA-2a content in C2C12 myotubes through a RANKL/RANK interaction-independent mechanism. Together, this basic research proposal highlights the mutual cooperative interactions between skeletal muscle and bone and should open new physiological mechanisms for RANK/RANKL/OPG pathway.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2016-05845
Name nom
Frenette, Jérôme
Department département
Réadaptation (physiothérapie, ergothérapie) - Réadaptation (physiothérapie, ergo
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
35000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5504
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Animal physiology and metabolism
Research subject fr
Physiologie et métabolisme des animaux
Partie
2
Nb partie
5
Application title
Deciphering the role of RANK/RANKL/OPG in skeletal muscle
Keyword
NSERC
Application summary
The discovery of RANK/RANKL/OPG the receptor-activator of nuclear factor B (RANK), the receptor-activator of nuclear factor B ligand (RANKL), and the osteoprotegerin (OPG) pathway has been among the most important advances in bone biology and disease. RANK/RANKL/OPG form a key cytokine system for regulating osteoclast differentiation and function. RANKL is expressed by osteoblasts while RANK, its receptor, is expressed on pre-osteoclastic cells. The RANK/RANKL interaction induces the formation of multinucleated mature osteoclasts, ultimately causing bone resorption. However, the third protagonist, OPG, is also produced by osteoblasts and exerts an inhibitory effect on pre-osteoclastic differentiation. OPG, by binding to RANKL, inhibits the RANKL/RANK interaction and the subsequent osteoclastogenesis. The fact that OPG-null mice are osteoporotic is testimony to the physiological importance of OPG. OPG also serves as a decoy receptor for the tumour necrosis factor-related apoptosis-inducing ligand and increases cell survival by blocking the pro-apoptotic effects of the RANK/RANKL interaction. OPG is thus a very efficient anti-resorptive and anti-apoptotic agent. However, our recent publication in Am. J. Pathol. (2015) convincingly showed that OPG-Fc completely restores the function of fast-twitch extensor digitorum longus muscles and significantly improves the function of slow-twitch soleus and diaphragm muscles in mdx mice, indicating that OPG is not only a protector of bone but also skeletal muscles. In this proposal, we will use genetic and pharmacological approaches to determine how RANK/RANKL/OPG triad, known for its role in bone regulation, regulates skeletal muscle phenotype, muscle function and SERCA-2a content and SERCA activity. We have also accumulated substantial evidence to support the observation that RANKL binds to muscle RANK but RANKL/OPG would also have its own muscle receptor acting directly on skeletal muscle. We thus intend to pursue three specific aims over the next 5 years. (1) To understand the interplay between OPG, RANKL, mechanical loading and extracellular Ca2+ in muscle cells in culture. (2) To determine how extracellular Ca2+ influences muscle performance in dystrophic muscle RANK deficient mice. (3) To demonstrate that RANKL influences SERCA-2a content in C2C12 myotubes through a RANKL/RANK interaction-independent mechanism. Together, this basic research proposal highlights the mutual cooperative interactions between skeletal muscle and bone and should open new physiological mechanisms for RANK/RANKL/OPG pathway.